SCA
FOLD

Snowden Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History

Snowden Capital Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,508
Closed -$325K – 1224
2024
Q4 		$325K Sell
34,508
-452
-1% -$4.7K 0.01% 949
2024
Q3 		$373K Sell
34,960
-15,104
-30% -$164K 0.01% 899
2024
Q2 		$497K Buy
50,064
+299
+0.6% +$3.07K 0.01% 756
2024
Q1 		$586K Sell
49,765
-833
-2% -$10.7K 0.02% 691
2023
Q4 		$718K Sell
50,598
-3,011
-6% -$34.2K 0.03% 538
2023
Q3 		$652K Sell
53,609
-4,452
-8% -$57.4K 0.03% 531
2023
Q2 		$729K Sell
58,061
-555
-0.9% -$6.59K 0.03% 569
2023
Q1 		$650K Buy
58,616
+768
+1% +$9.47K 0.03% 615
2022
Q4 		$706K Buy
57,848
+18,535
+47% +$209K 0.03% 554
2022
Q3 		$410K Buy
39,313
+12,804
+48% +$143K 0.02% 735
2022
Q2 		$284K Buy
+26,509
New +$218K 0.01% 894

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Snowden Capital Advisors's FOLD Position: Q1 2025 in Review

Snowden Capital Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 34,508 shares — an estimated $325K sold.

Snowden Capital Advisors first reported a position in FOLD in Q2 2022 and held it in 11 quarters. The position peaked at $729K in Q2 2023. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • Snowden Capital Advisors reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Snowden Capital Advisors sold 34,508 Amicus Therapeutics shares in Q1 2025, an estimated $325K.
  • Snowden Capital Advisors first reported a position in Amicus Therapeutics in Q2 2022 and held it in 11 quarters.
  • Snowden Capital Advisors's Amicus Therapeutics position peaked at $729K in Q2 2023.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Snowden Capital Advisors's 13F filing for Q1 2025, filed 14 May 2025.